Table 3.
Long-term outcomes
| Feature/outcome | Count or mean | % or standard deviation |
|---|---|---|
| Patients | 803 | – |
| Events up to 1 month of follow-up | ||
| Major adverse eventa | 38 | 4.7% |
| Death | 31 | 3.9% |
| Cardiovascular death | 25 | 3.1% |
| Stroke | 11 | 1.4% |
| Myocardial infarction | 0 | – |
| Major vascular complication | 9 | 1.1% |
| Life-threatening bleeding | 8 | 1.0% |
| Permanent pacemaker implantation | 81 | 10.1% |
| Rehospitalization for cardiovascular causes | 2 | 0.2% |
| Valve-related dysfunction requiring repeat procedure | 2 | 0.2% |
| Bioprosthetic valve failure | 31 | 3.9% |
| Endocarditis | 0 | – |
| Follow-up (years) | 3.1 | 1.5 |
| Cumulative events | ||
| Major adverse eventa | 301 | 37.5% |
| Death | 282 | 35.1% |
| Cardiovascular death | 190 | 23.7% |
| Stroke | 17 | 2.1% |
| Myocardial infarction | 5 | 0.6% |
| Major vascular complication | 40 | 5.0% |
| Life-threatening bleeding | 18 | 2.2% |
| Permanent pacemaker implantation | 126 | 15.7% |
| Rehospitalization for cardiovascular causes | 72 | 9.0% |
| Valve-related dysfunction requiring repeat procedure | 9 | 1.1% |
| Bioprosthetic valve failure | 284 | 35.4% |
| Endocarditis | 4 | 0.5% |
| New York Heart Association class | ||
| I | 99 | 30.6% |
| II | 154 | 47.5% |
| III | 68 | 21.0% |
| IV | 3 | 0.9% |
aDeath, stroke, myocardial infarction, and reintervention for valve degeneration